Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Depreciation and Depletion (2019 - 2025)

Eton Pharmaceuticals' Depreciation and Depletion history spans 7 years, with the latest figure at $8000.0 for Q3 2025.

  • For Q3 2025, Depreciation and Depletion rose 172.73% year-over-year to $8000.0; the TTM value through Sep 2025 reached $62000.0, up 129.63%, while the annual FY2024 figure was $50000.0, 13.64% up from the prior year.
  • Depreciation and Depletion for Q3 2025 was $8000.0 at Eton Pharmaceuticals, up from $4000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $84000.0 in Q1 2021 and bottomed at -$11000.0 in Q3 2024.
  • The 5-year median for Depreciation and Depletion is $13000.0 (2022), against an average of $18000.0.
  • The largest YoY upside for Depreciation and Depletion was 216.67% in 2024 against a maximum downside of 222.22% in 2024.
  • A 5-year view of Depreciation and Depletion shows it stood at $23000.0 in 2021, then crashed by 43.48% to $13000.0 in 2022, then decreased by 7.69% to $12000.0 in 2023, then surged by 216.67% to $38000.0 in 2024, then tumbled by 78.95% to $8000.0 in 2025.
  • Per Business Quant, the three most recent readings for ETON's Depreciation and Depletion are $8000.0 (Q3 2025), $4000.0 (Q2 2025), and $12000.0 (Q1 2025).